Robert Johnson, MD
Pulmonary Disease · Goshen, NYNPI 1205858024
Payments from drug & device makers
Across 340 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Boehringer Ingelheim$1K
- Regeneron Healthcare Solutions, Inc.$314
- Pfizer$269
- Mallinckrodt Hospital Products Inc.$260
- plus $697 from 14 others
What the payments were for
- Food & beverage$5,79897%
- Education$1903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 112 | $2,025 |
| GSK | 93 | $1,315 |
| Boehringer Ingelheim | 56 | $1,108 |
| Regeneron Healthcare Solutions, Inc. | 15 | $314 |
| Pfizer | 18 | $269 |
| Mallinckrodt Hospital Products Inc. | 10 | $260 |
| Sanofi | 11 | $196 |
| Actelion Pharmaceuticals US, Inc. | 3 | $127 |
| Philips North America LLC | 2 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Mylan Specialty L.p. | 3 | $43 |
| Sunovion Pharmaceuticals Inc. | 3 | $37 |
| Exact Sciences | 2 | $36 |
| Genentech USA, Inc. | 2 | $27 |
| Novartis | 2 | $25 |
| Amgen | 1 | $19 |
| Lilly USA, LLC | 1 | $14 |
| Merck | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$5,988 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 495 | $500,581 |
| OfevNintedanib Esylate | 27 | $400,955 |
| Breo ElliptaFluticasone/Vilanterol | 269 | $163,680 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 148 | $126,378 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $109,777 |
| EliquisApixaban | 73 | $58,085 |
| Incruse ElliptaUmeclidinium Bromide | 84 | $36,564 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $33,941 |
| FarxigaDapagliflozin Propanediol | 22 | $28,515 |
| XareltoRivaroxaban | 25 | $28,492 |
| JanuviaSitagliptin Phosphate | 28 | $26,587 |
| Spiriva RespimatTiotropium Bromide | 26 | $23,015 |
| RybelsusSemaglutide | 17 | $22,980 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 559 | $21,490 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $17,587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,315 | $730,398924 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat, Tradjenta | $1,108 | $477,318131 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Bevespi Aerosphere | $2,025 | $183,263226 claims |
| PfizerEliquis | $269 | $58,08573 claims |
| MerckJanuvia, Dulera, Belsomra | $13 | $37,84358 claims |
| Johnson & JohnsonXarelto | $13 | $28,49225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Goshen
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.